Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Multicenter Phase II Study in Patients With High Risk Breast Cancer With Capecitabine Versus Vinorelbine With Pathologic Residual Tumors After Preoperative Chemotherapy Secondary ID

NCT03703427 is registered in ClinicalTrials.gov with Zhiyong Yu as lead sponsor.

NCT NCT03703427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03703427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Multicenter Phase II Study in Patients With High Risk Breast Cancer With Capecitabine Versus Vinorelbine With Pathologic Residual Tumors After Preoperative Chemotherapy Secondary ID
Lead sponsor
Zhiyong Yu
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2018
Completion date
November 30, 2025
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pathologic residual cancer cells